Novel Coronavirus (COVID-19)
Vaccines Forecast
SARS-CoV-2 emerged in Wuhan in December 2019 and, within months, forced the fastest vaccine development effort in history. Six years on, the World Health Organization ended the Public Health Emergency of International Concern back in May 2023, and COVID-19 has settled into an endemic, seasonal respiratory disease pattern alongside influenza and RSV, still causing thousands of hospitalisations worldwide every month and driving a recurring, twice-yearly cycle of strain-composition updates. This is a comprehensive, wide geography commercial assessment of the mature COVID-19 vaccine market, covering Comirnaty, Spikevax and Nuvaxovid, the next generation of mucosal candidates now in clinical trials, and drawing on VacZine Analytics' long standing, independent authority in respiratory vaccine markets.
- Format
- Executive presentation + interactive Excel model
- Coverage
- 63 countries (Western, SE Asia, LATAM, Far East) plus global scenarios
- Indications
- Primary series, boosters, at-risk & seasonal segments
- Forecast horizon
- To 2045
- Approach
- Adjustable scenario-based model
- Base edition
- 2022
- Availability
- Syndicated / bespoke
WHO since December 2019
WHO to date (likely an undercount)
Comirnaty, Spikevax, Nuvaxovid
adjustable demand model
From pandemic emergency to endemic, seasonal respiratory virus
SARS-CoV-2 caused the defining public health emergency of a generation. This review sets out the virology and pandemic history, then turns to COVID-19's current, considerably reduced but still real, endemic burden and the R&D landscape now built around it.
Pathogen overview - SARS-CoV-2 (COVID-19)
SARS-CoV-2, the novel coronavirus responsible for COVID-19, emerged from Wuhan City, Hubei Province, China, in late December 2019, causing a cluster of atypical pneumonia cases traced to stallholders at a seafood wholesale market. The World Health Organization designated the outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and declared a global pandemic on 11 March 2020. SARS-CoV-2 is a betacoronavirus related to MERS-CoV (2012) and SARS-CoV-1 (2003), both far more lethal but far less transmissible, and to the two endemic human betacoronaviruses OC43 and HKU1, which have circulated as mild "common cold" pathogens for decades and offer a plausible long-run precedent for where COVID-19 is now heading.
On 5 May 2023, WHO Director-General Dr Tedros Adhanom Ghebreyesus formally ended the COVID-19 PHEIC, citing over a year of declining mortality, easing pressure on health systems and rising population immunity from vaccination and prior infection. Later that year, WHO shifted member states from daily to weekly case and death reporting, formally recognising the transition from emergency response to routine, endemic surveillance. Cumulative figures reported to WHO since December 2019 now stand at more than 776 million confirmed cases and over 7 million confirmed deaths, though WHO and independent trackers agree these figures understate the true toll given patchy testing and reporting once emergency-era surveillance wound down; several formerly continuous trackers, including Johns Hopkins University's dashboard and Worldometer's tracker, have themselves stopped daily updates for exactly this reason.
Today's burden looks entirely different in scale. In the four weeks from 15 June to 12 July 2026, WHO recorded just 1,233 new COVID-19 hospitalisations across 27 reporting countries and 54 new ICU admissions across 21 countries, a small fraction of pandemic-era peaks. The virus now follows a recognisably seasonal pattern in both hemispheres, tracked through a lineage tree that has moved well beyond the original Wuhan strain, through Alpha, Delta and Omicron, to today's dominant JN.1 descendants. As of mid-2026 the globally dominant lineage is XFG, nicknamed "Stratus," with US CDC surveillance showing XFG.1.1, XFG and XFG.14.1 sublineages accounting for the largest shares of sequenced cases. Because these variants continue to drift antigenically, WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) and the US FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) now run a twice-yearly strain-selection cycle much like that used for seasonal influenza, most recently recommending a monovalent JN.1-lineage vaccine, updated in December 2025 to target LP.8.1 as the preferred antigen, with JN.1/KP.2 formulations remaining acceptable alternatives.
A settled three-vaccine market, with mucosal candidates queuing behind it
The frantic multi-platform race of 2020 to 2022 has consolidated into a smaller, seasonally-updated market. Janssen's JCOVDEN and AstraZeneca's Vaxzevria have both been withdrawn on commercial grounds, leaving three Western vaccines in regular use, while a new generation of intranasal and oral, mucosal-immunity candidates works through early clinical trials.
-
Pfizer / BioNTechApproved & marketedComirnaty (BNT162b2, mRNA) Fully FDA-approved
The best-selling COVID-19 vaccine of the pandemic era remains fully approved in the US and widely authorised elsewhere, with its formulation updated each season under the WHO/FDA strain-selection cycle. On 29 July 2026 the European Commission authorised Pfizer/BioNTech's XFG-adapted 2026/27-season formula for use from 6 months of age across the EU/EEA, following a positive CHMP opinion on 23 July 2026. On 27 August 2026 the FDA formally approved the equivalent US formula, Comirnaty XFG, via supplemental Biologics License Application; reflecting the narrower post-2025 ACIP recommendation, the US approval covers adults aged 65 and over and those aged 5-64 with an underlying condition conferring high risk of severe COVID-19, rather than the general population. -
ModernaApproved & marketedSpikevax (mRNA-1273, mRNA) Fully FDA-approved
Also fully approved and updated each season alongside Comirnaty. Moderna's own 2025 results describe COVID-19 as having "transitioned to a seasonal respiratory vaccine," with full-year COVID product sales down sharply year-on-year as demand normalised from pandemic-era volumes to a smaller, recurring autumn/winter campaign. On 27 August 2026 the FDA approved Moderna's XFG-adapted 2026/27-season formulas of both Spikevax, for those aged 6 months to 64 years with a high-risk condition plus all adults 65 and over, and its newer-generation vaccine mNEXSPIKE (mRNA-1283), for the same at-risk group from age 12 plus all adults 65 and over, giving Moderna two approved products in the same reformulation cycle as Pfizer/BioNTech's and Novavax/Sanofi's XFG updates. On 5 November 2026 Moderna announced that Health Canada had authorised its combination influenza/COVID-19 vaccine mCOFLU (mRNA-1083) for adults aged 50 and over, alongside its standalone mRNA seasonal-flu vaccine mFLUSIVA (mRNA-1010); Moderna said Canada is the first country to authorise both products together, with the same combination vaccine already approved in the EU in April 2026 (as mCOMBRIAX) and under regulatory review elsewhere, giving Moderna a second approved combination flu-COVID candidate alongside Sanofi/Novavax's combination vaccine now in Phase 3 trials. -
Novavax / SanofiApproved & marketedNuvaxovid (NVX-CoV2373, protein-based, adjuvanted) Commercial lead transferred to Sanofi
The field's main non-mRNA option, offered as an alternative platform for those preferring a more conventional recombinant-protein vaccine. Novavax transferred lead commercial responsibility for Nuvaxovid to Sanofi beginning with the 2025/26 season in a number of markets including the US, retaining royalties on Sanofi's sales, a clear signal of the category's move into steady-state, franchise-style commercialisation rather than standalone pandemic-era supply. In its Q2 2026 results, released 6 August 2026, Novavax confirmed Sanofi is extending Nuvaxovid's commercial reach with new launches in the UK, Germany and Canada from 2026 onward, and is in advanced regulatory discussions on the timing of a Phase 3 trial for a combined COVID-19/influenza vaccine, a filing that would trigger a $125 million milestone payment to Novavax under the companies' licensing agreement. In its Q3 2026 results, released 5 November 2026, Novavax confirmed that Sanofi had begun dosing patients in Europe in October 2026 in that Phase 3 trial of a combined influenza/COVID-19 (CIC) vaccine, pairing Sanofi’s Efluelda high-dose flu vaccine with Nuvaxovid, which triggered the $125 million milestone payment to Novavax; Sanofi intends to start a separate US Phase 3 CIC trial in 2027 to support US approval, with a further $225 million payable to Novavax on a potential US launch. On 28 August 2026 Novavax announced that the XFG-adapted Nuvaxovid formulation had now received 2026/27-season regulatory approval in the US and EU via Sanofi and, via commercial partner Takeda, in Japan, where Nuvaxovid was the second most-used COVID-19 vaccine over the 2025/26 season; Novavax earns royalties and annual approval milestones under both partnership agreements. -
CastleVaxPhase II, intranasalCVAX-01 Newcastle disease virus vector, mucosal
Developed with the Icahn School of Medicine at Mount Sinai and supported by BARDA's Project NextGen, this intranasal candidate began Phase II dosing of around 200 US adults, including older and higher-risk participants, in November 2025, comparing nasal delivery against an approved injectable mRNA vaccine for both systemic and mucosal immune response. -
CodagenixPhase I complete, intranasalCoviLiv Live-attenuated, mucosal
A live-attenuated intranasal candidate, also supported by Project NextGen, that reported strong seroresponse and mucosal immunity in Phase I volunteers along with broad cellular responses spanning several conserved SARS-CoV-2 proteins, a design rationale aimed at variant-resilient protection rather than repeated strain-matched updates. -
VaxartPhase IIb, oralVXA-CoV2-3.3 Oral tablet, BARDA/Project NextGen-funded
On 6 July 2026 Vaxart reported topline 12-month safety data from the 400-participant sentinel-cohort of its BARDA-backed Phase IIb trial, comparing its oral pill candidate against an approved mRNA booster, with no vaccine-related serious adverse events in either arm. BARDA modified its contract on 25 June 2026, bringing total funding toward completion of the roughly 5,085-participant main cohort to approximately $345 million under Project NextGen, with full efficacy and safety data expected in H1 2027. -
WHO TAG-CO-VAC & US FDA VRBPACTwice-yearly strain selectionAntigen composition review cycle
Now run on an influenza-like twice-yearly cadence, this process reviews circulating variants and vaccine performance data from manufacturers to set the recommended antigen for each season, most recently affirming LP.8.1 in December 2025 while flagging the rising XFG lineage for the following cycle.
COVID-19 vaccines have moved from emergency, government-procured pandemic supply to a smaller, recurring autumn/winter commercial franchise sold alongside influenza and RSV shots. Moderna's own 2025 COVID product sales fell by roughly 40% year-on-year as pandemic-era advance purchase agreements completed and overall demand normalised, while Novavax handed lead commercialisation of Nuvaxovid to Sanofi for the 2025/26 season onward. At the same time, US COVID-19 vaccination policy has moved from a universal recommendation to individual, shared clinical decision-making for most people under 65, following changes at HHS and ACIP through 2025 that remain subject to ongoing legal and political scrutiny. That scrutiny continued into the 2026/27 reformulation cycle: with ACIP still not reconstituted following a federal judge's ruling that its 2025 membership was unlawfully appointed, the CDC did not open vaccine ordering through the Vaccines for Children programme - which supplies roughly half of US children, including uninsured and Medicaid-eligible groups - until 29 September 2026, around a month after the FDA's 27 August approvals, prompting Congressional enquiries into the delay. Internationally, WHO published a new position paper on COVID-19 vaccines on 31 July 2026 (Weekly Epidemiological Record No. 30), formally replacing its earlier interim, pandemic-era guidance with longer-term global policy: it recommends at least one annual dose - two doses around six months apart preferred - for the highest-priority groups (the oldest adults, a national threshold of 75-80+ suggested, adults 60 and over with major chronic conditions, care-home residents and the moderately-to-severely immunocompromised), while leaving routine vaccination of healthy children and younger adults to national discretion, a materially more selective global benchmark than pandemic-era universal recommendations. The VacZine Analytics model quantifies the resulting commercial opportunity across adjustable coverage, pricing and booster-schedule scenarios, and across both the major Western economies and 63 tracked emerging markets.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report with a wide geographic focus, spanning disease burden, the R&D competitive landscape and adjustable, scenario-based demand forecasting for a now-mature, seasonal vaccine market, to 2045.
Value/volume demand modelling to 2045 across 63 tracked countries (Western economies, SE Asia, LATAM, Far East), plus global, all-countries scenarios.
Full review of Comirnaty, Spikevax and Nuvaxovid, plus next-generation mucosal candidates from CastleVax and Codagenix now in clinical trials.
A fully adjustable model spanning launch date, target-group sequencing, coverage assumptions, seasonal versus pandemic-era pricing, and booster schedule.
Full review of SARS-CoV-2's virology and pandemic history, alongside its current endemic burden, variant tracking and seasonal case patterns.
Dedicated treatment of seasonal versus pandemic-era pricing dynamics, private/public payer split, and the annual or bi-annual booster schedule question.
Designed as a practical tool to support portfolio, investment and market-entry decisions in a now-mature, seasonally-recurring vaccine category.
A glimpse of the commercial model
The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Segment | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| Primary series | Western markets | General adult | Marketed | Modelled |
| Seasonal booster | SE Asia / LATAM / Far East | At-risk elderly | Marketed | Modelled |
| Paediatric primary series | Western markets | Paediatric | Marketed (shared decision-making) | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the now-mature COVID-19 vaccine market.
- Executive presentation - virology and pandemic history, current endemic burden and variant tracking, competitive environment review and pricing/policy discussion
- MS-Excel value/volume forecast model - demand outputs to 2045 across all relevant target segments and regions
- Wide geography coverage - 63 tracked countries (Western economies, SE Asia, LATAM, Far East) plus global, all-countries scenarios, to an agreed specification and timeframe
- Fully adjustable scenario controls - launch date, target-group sequence, percent coverage per group, percent at-risk/private sector, seasonal versus pandemic price, annual or bi-annual schedule, boosters per schedule
- Competitor intelligence - Comirnaty, Spikevax, Nuvaxovid, and the CastleVax/Codagenix mucosal-candidate pipeline
- Updated epidemiology module - current global burden data, XFG/JN.1-lineage variant tracking and the WHO/FDA strain-selection cycle
- Early decision-making support - new product strategy, seasonal pricing considerations and market entrance guidance for a mature, recurring category
Built for organisations navigating a mature, seasonal COVID-19 market
Most valuable to teams assessing the COVID-19 vaccine market against their own pipeline, BD ambitions or investment thesis, now that the category has settled into a recurring seasonal pattern alongside influenza and RSV.
Vaccine developers
Positioning and commercial feasibility assessment for next-generation, mucosal and variant-resilient COVID-19 candidates.
Corporate strategy & BD
Validate the size and shape of the now-seasonal COVID-19 franchise opportunity alongside existing influenza and RSV portfolios.
Investors & analysts
Independent assessment of pipeline risk and revenue trajectory for Pfizer, Moderna, Novavax/Sanofi and emerging mucosal-vaccine entrants.
Public health & immunisation programmes
Demand modelling to support seasonal campaign planning against a shifting evidence and policy backdrop, presented factually and without a political position.
Researchers & academia
Comprehensive epidemiology, variant surveillance and R&D landscape for translational and health-economic research planning.
Market access & policy
Pricing benchmarks, payer-channel assumptions and a neutral summary of the evolving US and international recommendation landscape.
VacZine Analytics has long standing expertise in respiratory diseases, tracking this market continuously since the earliest days of the pandemic and following it through every phase of the emergency response, the pandemic-to-endemic transition, and now its settled, seasonal commercial pattern. This is a genuinely comprehensive analysis with a wide geographic focus, spanning the major Western economies and 63 tracked emerging markets, and it has been well received by clients across the field for the depth of its epidemiology, competitive landscape and scenario-modelling coverage. Few groups have followed this market as closely across its full pandemic-to-endemic arc, and that recognised, independent expertise underpins everything in the analysis.
This report was last published in 2022; any refresh would incorporate the current global burden and variant picture, the WHO/FDA strain-selection cycle, Novavax's transfer of Nuvaxovid commercialisation to Sanofi, the evolving US ACIP/CDC recommendation landscape, and the CastleVax and Codagenix mucosal candidates now in clinical trials. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc COVID-19 vaccine analysis, a briefing call is included on request.